Everything biologic and biosimilar in-house counsel need to know about COVID-19

In the first session of our 2020 webinar series, we discussed the key responses to the COVID-19 pandemic in Europe and the United States that impact biologics and biosimilars.

Many of the top-selling drugs worldwide are biologics, and several companies are seeking to produce biosimilars to compete in these lucrative markets. However, they are facing a great deal of uncertainty due to ever-changing emergency policies aimed at addressing COVID-19.

In this session we focussed on critical developments impacting biologic and biosimilar companies, including:

• regulatory responses and challenges in the US and Europe
• changes in patent office policies and proceedings
• developments in the court systems, and
• dealing with contractual and supply chain issues.